Question explored with the scientific record
Does pregabalin help with panic attacks?
Pregabalin can reduce panic attack symptoms, but the evidence for it is thin, industry-funded, and short on hard outcomes.
The retrieved evidence includes only one human study on pregabalin for panic disorder: a one-year open-label safety trial with 135 panic patients [3]. Open-label means both patient and doctor knew they were getting the drug, which inflates perceived benefit. The study was funded by the manufacturer (Pfizer) [3]. It reported that 51.3% of all patients were "responders" on a clinician-rated severity scale, but it had no placebo group to compare against [3]. Without a control group, you cannot tell how much improvement came from the drug versus time or expectation.
The animal studies show pregabalin binds to calcium channels and reduces release of stress-related neurotransmitters [1][2]. That mechanism plausibly dampens panic. But mechanism is not proof. The one-year study also recorded substantial side effects: 24.4% of patients gained weight, 12.5% had dizziness, and 7.6% had drowsiness [3]. These are real trade-offs.
| Outcome | Pregabalin group (open-label) |
|---|---|
| Responder rate (CGI-S) | 51.3% |
| Weight gain | 24.4% |
| Dizziness | 12.5% |
| Somnolence | 7.6% |
No retrieved study compared pregabalin to a placebo or to standard treatments like SSRIs for panic attacks. No study measured how many full-blown panic attacks it prevented. The long-term safety data beyond one year does not exist in these records.
My call: pregabalin may help some people with panic, but the evidence base is too weak and too conflicted to call it proven. Confidence: low.
Sources used 3
-
Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
The study investigates the anxiolytic effects of pregabalin in rat models of anxiety, demonstrating its potential as a novel anxiolytic agent with a specific mechanism of action involving the alpha-2-delta subunit of voltage-dependent calcium channels.
DOI: 10.1038/sj.bjp.0703794 -
Pharmacology and mechanism of action of pregabalin: The calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discovery
A comprehensive review of pregabalin’s pharmacology demonstrating that its high-affinity binding to the alpha2-delta subunit of voltage-gated calcium channels underlies its anticonvulsant, analgesic, and anxiolytic actions—rather than actions at GABA receptors—and outlining the …
DOI: 10.1016/j.eplepsyres.2006.09.008 -
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
This study evaluates the long-term safety and tolerability of pregabalin in patients with generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder (PD) over a one-year open-label treatment period, finding it generally well tolerated with sustained imp…
DOI: 10.1185/03007995.2013.820694